The New Obesity Drugs: What Cardiac Practitioners Need to Know CardiOhio Podcast

Please join our special guest Dr. Ian Neeland from University Hospitals in Cleveland, to discuss the intersection of obesity and cardiovascular disease, and specifically the roles of the new agents semaglutide and tirzepatide. We discuss the recent data on cardiovascular outcomes with these agents, assessing patient candidacy, and tips for initiating and monitoring therapy. We also reviewed the complementary role of bariatric surgery and pharmacotherapy to improve cardiac outcomes.For m...